{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:40:55Z","timestamp":1787701255572,"version":"build-2784847793"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long-acting injectable cabotegravir plus rilpivirine (LAI CAB + RPV) represents an important advance in HIV treatment, offering an alternative to daily oral antiretroviral therapy (ART) for people with HIV (PWH) who are virologically suppressed. This narrative review aims to (i) evaluate the effectiveness and safety of LAI CAB + RPV in real-world clinical practice; (ii) assess outcomes in key subgroups, including women, older adults, people with elevated BMI, transgender people, and those with adherence challenges; and (iii) discuss practical and implementation considerations relevant to routine care. We synthesized the most up-to-date evidence from peer-reviewed publications and major international HIV conferences. Recent real-world cohort studies consistently report high rates of virological suppression (typically &amp;gt;90%) and low rates of confirmed virological failure, even in diverse populations and those with complex social or medical needs. Injection site reactions are common but rarely lead to discontinuation, and overall tolerability is high. Evidence suggests that LAI CAB + RPV can be successfully implemented in clinical practice, including among individuals with a history of non-adherence, provided that appropriate support systems are in place. However, current data are limited by short follow-up periods and relatively small sample sizes, especially in underrepresented groups such as women, older adults, people with high BMI, or transgender people. Further research is needed to clarify long-term outcomes and optimize patient selection. In summary, LAI CAB + RPV is a promising and well-tolerated option for maintaining virological suppression in routine care, with the potential to address important unmet needs across a broad spectrum of PWH. Ongoing studies will help define its optimal use and long-term benefits in real-world settings.<\/jats:p>","DOI":"10.1093\/jac\/dkaf246","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:44:38Z","timestamp":1755020678000},"page":"2565-2586","source":"Crossref","is-referenced-by-count":6,"title":["Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-8014","authenticated-orcid":false,"given":"Luis","family":"Buz\u00f3n-Mart\u00edn","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-8358","authenticated-orcid":false,"given":"Alfonso","family":"Cabello","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Health Research Institute-FJD, Universidad Aut\u00f3noma de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-967X","authenticated-orcid":false,"given":"Alberto","family":"D\u00edaz de Santiago","sequence":"additional","affiliation":[{"name":"HIV\/AIDS, PrEP and STI Unit, Department of Internal Medicine, Puerta de Hierro University Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J","family":"Galindo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases-Internal Medicine, Hospital Cl\u00ednico Universitario de Valencia INCLIVA , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Universitario Virgen de las Nieves , Granada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romero-Palacios","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, University Hospital Puerto Real, Institute for Biomedical Research and Innovation of Cadiz (INIBICA) , Cadiz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-114X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Troya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"4","key":"2025100314230208200_dkaf246-B1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.35772\/ghm.2023.01013","article-title":"Four decades of continuing innovations in the development of antiretroviral therapy for HIV\/AIDS: Progress to date and future challenges","volume":"5","author":"Ghosh","year":"2023","journal-title":"Glob Health Med"},{"key":"2025100314230208200_dkaf246-B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2025100314230208200_dkaf246-B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/COH.0000000000000904","article-title":"Use of long-acting injectable cabotegravir\/rilpivirine in people with HIV and adherence challenges","volume":"20","author":"Christopoulos","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"key":"2025100314230208200_dkaf246-B4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"2025100314230208200_dkaf246-B5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2025100314230208200_dkaf246-B6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"issue":"10267","key":"2025100314230208200_dkaf246-B7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"2025100314230208200_dkaf246-B8","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"issue":"11","key":"2025100314230208200_dkaf246-B9","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"9","key":"2025100314230208200_dkaf246-B10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2025100314230208200_dkaf246-B11","doi-asserted-by":"publisher","first-page":"ofab439","DOI":"10.1093\/ofid\/ofab439","article-title":"Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 study","volume":"8","author":"Smith","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B12","author":"U.S. Department of Health and Human Services (DHHS)"},{"key":"2025100314230208200_dkaf246-B13","author":"EACS","year":"2024"},{"issue":"S6","key":"2025100314230208200_dkaf246-B14","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Real-world outcomes of cabotegravir and rilpivirine for treating PLHIV in Spain: a multicenter, ambispective and nationwide study (the RELATIVITY cohort)","volume":"27","author":"Martin","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025100314230208200_dkaf246-B15","author":"Hsu"},{"issue":"Suppl 6","key":"2025100314230208200_dkaf246-B16","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Effectiveness of long-acting ART with cabotegravir\/rilpivirine in the ICONA cohort","volume":"27","author":"Gagliardini","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"2025100314230208200_dkaf246-B17","doi-asserted-by":"publisher","first-page":"ofae326","DOI":"10.1093\/ofid\/ofae326","article-title":"One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART study","volume":"11","author":"Muccini","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 6","key":"2025100314230208200_dkaf246-B18","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Use of long-acting cabotegravir and rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH-NA cohort-France","volume":"27","author":"Hessamfar","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025100314230208200_dkaf246-B19","author":"Jonsson-Oldenb\u00fcttel"},{"key":"2025100314230208200_dkaf246-B20","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"Suppl 6","key":"2025100314230208200_dkaf246-B21","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Real-life effectiveness, safety and acceptance of long-acting cabotegravir-rilpivirine: results from a large single-centre cohort","volume":"27","author":"Gonz\u00e1lez-Cord\u00f3n","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025100314230208200_dkaf246-B22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/cid\/ciae475","article-title":"Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters","volume":"80","author":"Guti\u00e9rrez","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025100314230208200_dkaf246-B23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"},{"key":"2025100314230208200_dkaf246-B24","author":"Liegeon"},{"key":"2025100314230208200_dkaf246-B25","author":"Shankaran"},{"issue":"4","key":"2025100314230208200_dkaf246-B26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/AID.2023.0108","article-title":"Favorable virological outcome, characteristics of injection site reactions, decrease in renal function biomarkers in Asian people with HIV receiving long-acting cabotegravir plus rilpivirine","volume":"40","author":"Adachi","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"2025100314230208200_dkaf246-B27","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jac\/dkae080","article-title":"Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals","volume":"79","author":"Cossu","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"2025100314230208200_dkaf246-B28","doi-asserted-by":"publisher","first-page":"ofad500.1450","DOI":"10.1093\/ofid\/ofad500.1450","article-title":"1615. Efficacy of long-acting cabotegravir and rilpivirine in a diverse group of patients in a real-world setting","volume":"10","author":"Yared","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B29","author":"CROI Conference"},{"key":"2025100314230208200_dkaf246-B30","author":"Resources | IAS Plus"},{"key":"2025100314230208200_dkaf246-B31","author":"HIV Glasgow"},{"key":"2025100314230208200_dkaf246-B32","author":"Pozniak"},{"key":"2025100314230208200_dkaf246-B33","author":"Schneider"},{"key":"2025100314230208200_dkaf246-B34","author":"Palacios"},{"issue":"Suppl 6","key":"2025100314230208200_dkaf246-B35","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Results at month 7 of CABO-CHANCE study: real-world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)","volume":"27","author":"Hidalgo Tenorio","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025100314230208200_dkaf246-B36","author":"Taramasso"},{"key":"2025100314230208200_dkaf246-B37","author":"Lagi"},{"issue":"10","key":"2025100314230208200_dkaf246-B38","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics ( SHARE LAI -net)","volume":"25","author":"Ring","year":"2024","journal-title":"HIV Med"},{"issue":"1","key":"2025100314230208200_dkaf246-B39","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S2352-3018(24)00269-8","article-title":"Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort","volume":"12","author":"Jongen","year":"2025","journal-title":"Lancet HIV"},{"key":"2025100314230208200_dkaf246-B40","author":"Levis"},{"key":"2025100314230208200_dkaf246-B41","author":"Frick"},{"issue":"1","key":"2025100314230208200_dkaf246-B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/COH.0000000000000897","article-title":"Long-acting antiretroviral therapy in the context of viral suppression","volume":"20","author":"Ring","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"2025100314230208200_dkaf246-B43","author":"Levis"},{"key":"2025100314230208200_dkaf246-B44","author":"Galindo Puerto"},{"key":"2025100314230208200_dkaf246-B45","author":"Moreno"},{"issue":"4","key":"2025100314230208200_dkaf246-B46","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/jac\/dkaf038","article-title":"Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research","volume":"80","author":"Rosas Cancio-Su\u00e1rez","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"2025100314230208200_dkaf246-B47","doi-asserted-by":"publisher","first-page":"ofad500.1443","DOI":"10.1093\/ofid\/ofad500.1443","article-title":"1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA\u00ae Cohort","volume":"10","author":"Sension","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B48","author":"Maguire"},{"key":"2025100314230208200_dkaf246-B49","author":"Troya"},{"issue":"Suppl 1","key":"2025100314230208200_dkaf246-B50","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/ofid\/ofae631.760","article-title":"Long-acting cabotegravir and rilpivirine in HIV individuals over 60 years: a real-world study (RELATIVITY cohort)","volume":"12","author":"Troya","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"2025100314230208200_dkaf246-B51","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"issue":"7","key":"2025100314230208200_dkaf246-B52","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025100314230208200_dkaf246-B53","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B54","author":"Buz\u00f3n Mart\u00edn"},{"key":"2025100314230208200_dkaf246-B55","author":"European Medicines Agency"},{"key":"2025100314230208200_dkaf246-B56","author":"European Medicines Agency"},{"key":"2025100314230208200_dkaf246-B57","author":"U.S. Food and Drug Administration"},{"issue":"5","key":"2025100314230208200_dkaf246-B58","doi-asserted-by":"publisher","first-page":"ofaf220","DOI":"10.1093\/ofid\/ofaf220","article-title":"Clinical outcomes and perspectives of people with human immunodeficiency virus type 1 twelve months after initiation of long-acting cabotegravir and rilpivirine in an observational real-world US study (BEYOND)","volume":"12","author":"Dandachi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B59","article-title":"Long-acting cabotegravir\/rilpivirine in real life: sex-based characteristics, PROs, and effectiveness","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); March 9\u201312, 2025; San Francisco, CA","author":"Gonz\u00e1lez-Cord\u00f3n"},{"issue":"10","key":"2025100314230208200_dkaf246-B60","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025100314230208200_dkaf246-B61","author":"Ramgopal"},{"key":"2025100314230208200_dkaf246-B62","author":"Lutz"},{"issue":"4","key":"2025100314230208200_dkaf246-B63","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"2025100314230208200_dkaf246-B64","author":"Czarnogorski"},{"issue":"Suppl 2","key":"2025100314230208200_dkaf246-B65","doi-asserted-by":"publisher","first-page":"ofac492.107","DOI":"10.1093\/ofid\/ofac492.107","article-title":"1584. CARISEL A hybrid III implementation effectiveness study of implementation of cabotegravir plus rilpivirine long acting (CAB+RPV LA) in EU health care settings key clinical and implementation outcomes by implementation arm","volume":"9","author":"De Wit","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B66","author":"Sinclair"},{"issue":"2","key":"2025100314230208200_dkaf246-B67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"issue":"4","key":"2025100314230208200_dkaf246-B68","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025100314230208200_dkaf246-B69","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae631","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long-acting cabotegravir for HIV treatment: a meta-analysis","author":"Navarro A","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025100314230208200_dkaf246-B70","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2025100314230208200_dkaf246-B71","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/QAD.0000000000003887","article-title":"Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine","volume":"38","author":"Rubenstein","year":"2024","journal-title":"AIDS Lond Engl"},{"issue":"1","key":"2025100314230208200_dkaf246-B72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis","volume":"79","author":"van Welzen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B73","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/cid\/ciae557","article-title":"Long-acting cabotegravir plus rilpivirine in people with HIV with adherence challenges and viremia: current data and future directions","volume":"80","author":"Davis","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B74","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf120","article-title":"Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy","author":"Hastie","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B75","doi-asserted-by":"publisher","first-page":"20499361221149773","DOI":"10.1177\/20499361221149773","article-title":"Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?","volume":"10","author":"Brizzi","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"2025100314230208200_dkaf246-B76","author":"Arribas"},{"key":"2025100314230208200_dkaf246-B77","author":"Adelakun"},{"key":"2025100314230208200_dkaf246-B78","author":"Hennessy"},{"issue":"4","key":"2025100314230208200_dkaf246-B79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2025100314230208200_dkaf246-B80","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1089\/apc.2022.0056","article-title":"Adherence to antiretroviral therapy in people living with HIV\/AIDS: a cross-sectional study","volume":"36","author":"Bomfim","year":"2022","journal-title":"AIDS Patient Care STDs"},{"key":"2025100314230208200_dkaf246-B81","author":"World Health Organization"},{"issue":"8","key":"2025100314230208200_dkaf246-B82","doi-asserted-by":"publisher","first-page":"ofad390","DOI":"10.1093\/ofid\/ofad390","article-title":"Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers","volume":"10","author":"Chen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025100314230208200_dkaf246-B83","author":"John"},{"key":"2025100314230208200_dkaf246-B84","author":"Rana"},{"key":"2025100314230208200_dkaf246-B85","author":"Mart\u00ednez Rebollar"},{"issue":"6","key":"2025100314230208200_dkaf246-B86","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s40121-022-00694-w","article-title":"Do ART and chemsex drugs get along? Potential drug-drug interactions in a cohort of people living with HIV who engaged in chemsex: a retrospective observational study","volume":"11","author":"De La Mora","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"3","key":"2025100314230208200_dkaf246-B87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/COH.0000000000000730","article-title":"Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages","volume":"17","author":"Waters","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"2025100314230208200_dkaf246-B88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/COH.0000000000000732","article-title":"Implementation of long-acting antiretroviral therapy in low-income and middle-income countries","volume":"17","author":"Cresswell","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"2025100314230208200_dkaf246-B89","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/QAI.0000000000003501","article-title":"Brief report: switching to long-acting CAB\/RPV: data from an Italian monocentric cohort","volume":"97","author":"Matone","year":"2024","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"6","key":"2025100314230208200_dkaf246-B90","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/cpt.3240","article-title":"Population pharmacokinetics of cabotegravir following oral administration and long-acting intramuscular injection in real-world people with HIV","volume":"115","author":"Thoueille","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2025100314230208200_dkaf246-B91","doi-asserted-by":"publisher","first-page":"e00204-24","DOI":"10.1128\/aac.00204-24","article-title":"Reply to Cossu et al., \u201cSwitching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV\u201d","volume":"68","author":"Han","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"19-20","key":"2025100314230208200_dkaf246-B92","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1111\/jocn.16126","article-title":"Dorsogluteal intramuscular injection depth needed to reach muscle tissue according to body mass index and gender: A systematic review","volume":"31","author":"Strohfus","year":"2022","journal-title":"J Clin Nurs"},{"key":"2025100314230208200_dkaf246-B93","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/jac\/dkaf127","article-title":"Ultrasound for long-acting injectable cabotegravir and rilpivirine in transgender individuals with implants: a new opportunity for normalization","volume":"80","author":"Troya","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6","key":"2025100314230208200_dkaf246-B94","doi-asserted-by":"publisher","first-page":"e26370","DOI":"10.1002\/jia2.26370","article-title":"Transforming HIV Care: intramuscular bimonthly cabotegravir and rilpivirine for transgender people with HIV in Spain (RELATIVITY cohort)","volume":"27","author":"Santiago A","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025100314230208200_dkaf246-B95","author":"Moreno"},{"key":"2025100314230208200_dkaf246-B96","author":"Calcagno"},{"issue":"2","key":"2025100314230208200_dkaf246-B97","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/cid\/ciae060","article-title":"Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modeling study","volume":"79","author":"Bettonte","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025100314230208200_dkaf246-B98","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11154-023-09796-3","article-title":"Relevance of body composition in phenotyping the obesities","volume":"24","author":"Salm\u00f3n-G\u00f3mez","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"2025100314230208200_dkaf246-B99","doi-asserted-by":"publisher","first-page":"e0260604","DOI":"10.1371\/journal.pone.0260604","article-title":"Origin and evolution of HIV-1 subtype A6","volume":"16","author":"Abidi","year":"2021","journal-title":"PLoS One"},{"key":"2025100314230208200_dkaf246-B100","author":"Garc\u00eda"},{"issue":"3","key":"2025100314230208200_dkaf246-B101","doi-asserted-by":"publisher","first-page":"e0170221","DOI":"10.1128\/AAC.01702-21","article-title":"Impact of integrase sequences from HIV-1 subtypes A6\/A1 on the in vitro potency of cabotegravir or rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314230208200_dkaf246-B102","author":"Kityo"},{"issue":"10","key":"2025100314230208200_dkaf246-B103","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/cid\/ciad058","article-title":"Circulation of human immunodeficiency virus 1 A6 variant in the eastern border of the European Union\u2014dynamics of the virus transmissions between Poland and Ukraine","volume":"76","author":"Serwin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B104","author":"Deschanvres"},{"key":"2025100314230208200_dkaf246-B105","author":"Canavesi"},{"key":"2025100314230208200_dkaf246-B106","doi-asserted-by":"publisher","first-page":"ciae579","DOI":"10.1093\/cid\/ciae579","article-title":"Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir\/rilpivirine","author":"Maguire","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2025100314230208200_dkaf246-B107","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025100314230208200_dkaf246-B108","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5159873","article-title":"Long-acting injectable cabotegravir and rilpivirine in observational cohortstudies: a systematic review on virological failure, resistance, and re-suppression outcomes in virallysuppressed individuals living with HIV","author":"Ring","year":"2025","journal-title":"HIV Med"},{"key":"2025100314230208200_dkaf246-B109"},{"issue":"1","key":"2025100314230208200_dkaf246-B110","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/QAD.0000000000004040","article-title":"Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir\/rilpivirine","volume":"39","author":"Alagaratnam","year":"2025","journal-title":"AIDS Lond Engl"},{"issue":"4","key":"2025100314230208200_dkaf246-B111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/apc.2025.0010","article-title":"A Proposal for a tool to reduce the frequency of HIV RNA monitoring in people with HIV treated with long-acting antiretrovirals","volume":"39","author":"Cologgi","year":"2025","journal-title":"AIDS Patient Care STDs"},{"key":"2025100314230208200_dkaf246-B112","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/IDR.S406188","article-title":"Role of proviral HIV-1 DNA genotyping for people living with HIV (PLWH) who had low-level viremia while receiving antiretroviral therapy","volume":"16","author":"Lv","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025100314230208200_dkaf246-B113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing human immunodeficiency virus (HIV) proviral DNA to assess for the presence of HIV drug resistance","author":"Wensing","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2025100314230208200_dkaf246-B114","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/v16111697","article-title":"Archived HIV-1 drug resistance mutations: role of proviral HIV-1 DNA genotype for the management of virological responder people living with HIV","volume":"16","author":"Campagna","year":"2024","journal-title":"Viruses"},{"key":"2025100314230208200_dkaf246-B115","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/cid\/ciae141","article-title":"Reasons against routine determination of plasma trough levels in PWH treated with intramuscular long acting cabotegravir and rilpivirine as of today","volume":"80","author":"Buz\u00f3n-Mart\u00edn","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2025100314230208200_dkaf246-B116","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciz129","article-title":"Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure","volume":"69","author":"Joya","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025100314230208200_dkaf246-B117","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025100314230208200_dkaf246-B118","author":"Latham"},{"key":"2025100314230208200_dkaf246-B119","author":"Talarico"},{"key":"2025100314230208200_dkaf246-B120","author":"Thornhill"},{"key":"2025100314230208200_dkaf246-B121","author":"Latham"},{"key":"2025100314230208200_dkaf246-B122","author":"Fern\u00e1ndez-Hinojal"},{"issue":"1","key":"2025100314230208200_dkaf246-B123","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/QAI.0000000000003320","article-title":"Predictors of post-switch viremia in people with HIV on injectable cabotegravir\/rilpivirine","volume":"95","author":"Hill","year":"2024","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"2025100314230208200_dkaf246-B124","doi-asserted-by":"publisher","first-page":"ofae147","DOI":"10.1093\/ofid\/ofae147","article-title":"Low level viremia is associated with serious non-AIDS events in people with HIV","volume":"11","author":"Ganesan","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025100314230208200_dkaf246-B125","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMms2412286","article-title":"Long-acting HIV medicines and the pandemic inequality cycle - rethinking access","volume":"392","author":"Byanyima","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2025100314230208200_dkaf246-B126","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0000000000000900","article-title":"Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out","volume":"20","author":"Tembo","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"2025100314230208200_dkaf246-B127","author":"Christopoulos"},{"key":"2025100314230208200_dkaf246-B128","author":"Galindo Puerto"},{"key":"2025100314230208200_dkaf246-B129","author":"Llenas-Garc\u00eda"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2565\/63966701\/dkaf246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2565\/63966701\/dkaf246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:23:10Z","timestamp":1759515790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/10\/2565\/8223102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":129,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf246","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,6]]}}}